A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Elevated hsCRP

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-10-16

Study Completion Date

2024-12-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This Phase 2a clinical trial will evaluate the effectiveness, safety, and tolerability of increasing dose strengths of an oral daily medication, DFV890, administered for 12 weeks, to reduce key markers of inflammation related to CVD risk, such as IL-6 and IL-18, in approximately 24 people with known heart disease and an elevated marker of inflammation, hsCRP.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phase 2 Study in Vascular Inflammation on Patients After an Acute Coronary Syndrome Event

NCT00552188

Acute Coronary Syndrome

COMPLETED PHASE2

A First-in-human, 3-part Study of MRT-8102 in Healthy Participants and Participants at Cardiovascular Risk With Elevated CRP

NCT07119125

Healthy Volunteers Elevated CRP

RECRUITING PHASE1

Study Effect of VIA-2291 on Vascular Inflammation

NCT00358826

Coronary Artery Disease

COMPLETED PHASE2

Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular Inflammation in Subjects With Coronary Artery Disease

NCT00312052

Coronary Artery Disease

COMPLETED PHASE2

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

NCT01327846

Atherosclerosis

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a multi-center, randomized, placebo-controlled, participant- and investigator-blinded study to evaluate the efficacy, safety, and tolerability of intra-individual dose escalation of DFV890 for inflammatory marker reduction in participants with coronary heart disease and elevated hsCRP. The study consists of a screening period of up to 60 days, a treatment period of approximately 12 weeks, an end of treatment (EOT) visit on Day 85, which is one day after the last dose on Day 84, a follow-up period of approximately 1 week and a standard safety-follow-up call approximately 30 days following the last dose. The overall study duration is approximately 24 weeks and approximately 24 participants will be enrolled into the trial.

Participants meeting all eligibility criteria will be randomized in a 5:5:1:1 ratio to one of four treatment sequences (three DFV890 treatment sequences or a placebo-only sequence). The dose of DFV890 will be uptitrated (according to the specific treatment sequence that the participant is assigned to) approximately every three weeks at the scheduled visits on Days 22, 43 and 64.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Heart Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment Sequence 1

Participants will be administered Placebo and different doses of DFV890

Group Type EXPERIMENTAL

DFV890

Intervention Type DRUG

oral film-coated tablets

Placebo

Intervention Type DRUG

oral film-coated tablets

Treatment sequence 2

Participants will be administered Placebo and different doses of DFV890

Group Type EXPERIMENTAL

DFV890

Intervention Type DRUG

oral film-coated tablets

Placebo

Intervention Type DRUG

oral film-coated tablets

Treatment sequence 3

Participants will be administered different doses of DFV890

Group Type EXPERIMENTAL

DFV890

Intervention Type DRUG

oral film-coated tablets

Treatment sequence 4

Participants will be administered Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

oral film-coated tablets

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

DFV890

oral film-coated tablets

Intervention Type DRUG

Placebo

oral film-coated tablets

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male and female participants aged between 18 - 85 years (inclusive) at the start of screening will be included.
* Subjects must have a body mass index (BMI) within the range of 18 - 45 kg/m2. BMI = Body weight (kg) / \[Height (m)\]2
* Documented spontaneous myocardial infarction (MI) (diagnosed according to the universal MI criteria with or without evidence of ST segment elevation) at least 30 days before the start of screening.
* Participants must have hsCRP levels ≥ 2 mg/L at two timepoints during screening. Screening values must be separated by a minimum of 8 days. The initial hsCRP value must be a minimum of 30 days after the qualifying MI or after any percutaneous coronary intervention (PCI) performed separately from the qualifying MI.
* For participants on statin therapy (HMG-CoA reductase inhibitor), as clinically indicated, participants must be on a stable regimen (at least 4 weeks before randomization), with no planned statin dose changes over the course of the trial treatment period. Unplanned statin dose changes during the trial treatment period may occur.

Exclusion Criteria

* Patients receiving concomitant medications that are known to be strong or moderate inducers of cytochrome CYP2C9 enzyme and/or strong inducers of CYP3A, strong inhibitors of CYP2C9 and/or strong or moderate inhibitors of CYP3A and the treatment cannot be discontinued or switched to a different medication within 5 half-lives or 1 week (whichever is longer) prior to Day 1 and for the duration of the study.
* Patients with suspected or proven immunocompromised state at screening
* History of ongoing, chronic, or major recurrent infectious disease, at the discretion of the investigator, at the start of screening.
* Use of any biologic drugs targeting the immune system within 26 weeks of Day 1
* Multi-vessel Coronary Artery Bypass Graft (CABG) surgery within the past 6 months prior to the start of screening.
* Symptomatic Class IV heart failure (New York Heart Association) at the start of screening.
* Planned coronary revascularization (PCI or CABG) or any other major surgical procedure during the study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No